+

WO1996022068A3 - Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline - Google Patents

Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline Download PDF

Info

Publication number
WO1996022068A3
WO1996022068A3 PCT/US1996/001561 US9601561W WO9622068A3 WO 1996022068 A3 WO1996022068 A3 WO 1996022068A3 US 9601561 W US9601561 W US 9601561W WO 9622068 A3 WO9622068 A3 WO 9622068A3
Authority
WO
WIPO (PCT)
Prior art keywords
desmethylselegiline
methods
ent
selegiline
pharmaceutical compositions
Prior art date
Application number
PCT/US1996/001561
Other languages
English (en)
Other versions
WO1996022068A2 (fr
Inventor
Cheryl D Blume
Anthony R Disanto
Original Assignee
Somerset Pharmaceuticals Inc
Cheryl D Blume
Anthony R Disanto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc, Cheryl D Blume, Anthony R Disanto filed Critical Somerset Pharmaceuticals Inc
Priority to JP08522464A priority Critical patent/JP3036847B2/ja
Priority to CA002209892A priority patent/CA2209892C/fr
Priority to EP96904573A priority patent/EP0812188A2/fr
Priority to AU48644/96A priority patent/AU695359C/en
Priority to FI972988A priority patent/FI972988A7/fi
Priority to US08/679,328 priority patent/US6033682A/en
Priority to US08/679,330 priority patent/US6348208B1/en
Publication of WO1996022068A2 publication Critical patent/WO1996022068A2/fr
Publication of WO1996022068A3 publication Critical patent/WO1996022068A3/fr
Priority to NO19973261A priority patent/NO321830B1/no
Priority to HK98110118A priority patent/HK1009099A1/xx
Priority to US09/262,845 priority patent/US6299901B1/en
Priority to US09/315,840 priority patent/US6319954B1/en
Priority to US09/448,483 priority patent/US6210706B1/en
Priority to US09/800,040 priority patent/US6375979B2/en
Priority to US09/800,022 priority patent/US6455060B2/en
Priority to US09/805,281 priority patent/US6562364B2/en
Priority to US09/885,365 priority patent/US6420433B2/en
Priority to US09/895,718 priority patent/US6419948B2/en
Priority to US09/940,252 priority patent/US6528082B2/en
Priority to US09/960,277 priority patent/US6562365B2/en
Priority to US10/026,159 priority patent/US6699495B2/en
Priority to US10/251,727 priority patent/US6759053B2/en
Priority to US10/353,324 priority patent/US20030195260A1/en
Priority to US10/382,126 priority patent/US20030191191A1/en
Priority to US10/790,658 priority patent/US20040228907A1/en
Priority to US10/885,221 priority patent/US7144584B2/en
Priority to US11/290,772 priority patent/US20060167110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet des procédés et des compositions pharmaceutiques faisant appel à la desméthylsélégiline, un métabolite de la sélégiline, et à ses formes stéréoisomères. En particulier, la présente invention traite de nouvelles compositions et de procédés permettant d'utiliser la desméthylsélégiline et/ou l'ent-desméthylsélégiline, pour les maladies et les états réagissant à la sélégiline. Les maladies et les états réagissant à la sélégiline comprennent ceux entraînés par la dégénérescence des neurones ou par traumatisme nerveux ou ceux dûs à un dysfonctionnement du système immunitaire. La desméthylsélégiline, et/ou l'ent-desméthylsélégiline peut être administrée par voie orale ou selon un mode d'administration ne dépendant pas de l'absorption gastro-intestinale. La desméthylsélégiline est l'énantiomère R-(-) du N-méthyle-N(prop-2-ynyl)-2-aminophénylpropane et l'ent-destméthylsélégiline est l'énantiomère S(+). Les compositions décrites comprennent les isomères R-(-) et S-(+) ainsi que des mélanges de ces derniers. Des sels d'addition d'acide pharmaceutiquement acceptables peuvent être également utilisés. Des dosages efficaces comprennent une dose quotidienne d'au moins 0,0015 mg par kilogramme de poids corporel.
PCT/US1996/001561 1995-01-13 1996-01-11 Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline WO1996022068A2 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
JP08522464A JP3036847B2 (ja) 1995-01-13 1996-01-11 デスメチルセレギリンを用いる方法および医薬組成物
CA002209892A CA2209892C (fr) 1995-01-13 1996-01-11 Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline
EP96904573A EP0812188A2 (fr) 1995-01-13 1996-01-11 Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline
AU48644/96A AU695359C (en) 1995-01-13 1996-01-11 Methods and pharmaceutical compositions employing desmethylselegiline
FI972988A FI972988A7 (fi) 1995-01-13 1996-01-11 Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyli selegiliiniä
US08/679,328 US6033682A (en) 1995-01-13 1996-07-12 S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US08/679,330 US6348208B1 (en) 1995-01-13 1996-07-12 Methods and pharmaceutical compositions employing desmethylselegiline
NO19973261A NO321830B1 (no) 1995-01-13 1997-07-14 Desmetylselegilin eller salt derav, medikament omfattende forbindelsen, samt anvendelser derav
HK98110118A HK1009099A1 (en) 1995-01-13 1998-08-24 Methods and pharmaceutical compositions employing desmethylselegiline
US09/262,845 US6299901B1 (en) 1995-01-13 1999-03-05 Methods and pharmaceutical compositions employing desmethylselegiline
US09/315,840 US6319954B1 (en) 1995-01-13 1999-05-21 S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US09/448,483 US6210706B1 (en) 1995-01-13 1999-11-24 S (+) Desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US09/800,022 US6455060B2 (en) 1995-01-13 2001-03-05 S(+) desmethylselegiline and its use to treat immune system dysfunction
US09/800,040 US6375979B2 (en) 1995-01-13 2001-03-05 S(+) desmethylselegiline and its use in transdermal delivery compositions
US09/805,281 US6562364B2 (en) 1995-01-13 2001-03-13 Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
US09/885,365 US6420433B2 (en) 1995-01-13 2001-06-20 S(+) desmethylselegiline and drug withdrawal
US09/895,718 US6419948B2 (en) 1995-01-13 2001-06-29 R(-)desmethylselegiline and its use in transdermal delivery compositions
US09/940,252 US6528082B2 (en) 1995-01-13 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
US09/960,277 US6562365B2 (en) 1995-01-13 2001-09-21 Methods employing R(−)-desmethylselegiline
US10/026,159 US6699495B2 (en) 1995-01-13 2001-12-21 Methods for treating multiple sclerosis employing desmethylselegiline
US10/251,727 US6759053B2 (en) 1995-01-13 2002-09-20 S(+) Desmethylselegiline and its use to treat ADHD
US10/353,324 US20030195260A1 (en) 1995-01-13 2003-01-28 Methods and pharmaceutical compositions employing S(+)-desmethylselegiline to treat neoplastic diseases or conditions
US10/382,126 US20030191191A1 (en) 1995-07-31 2003-03-04 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions
US10/790,658 US20040228907A1 (en) 1995-01-13 2004-03-01 Methods and pharmaceutical compositions employing desmethylselegiline
US10/885,221 US7144584B2 (en) 1995-01-13 2004-07-06 S(+) desmethylselegiline and its use to treat narcolepsy
US11/290,772 US20060167110A1 (en) 1995-01-13 2005-11-30 Methods for treating cerebrovascular disease by administering desmethylselegiline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37213995A 1995-01-13 1995-01-13
US08/372,139 1995-01-13
US60/011,979 1996-02-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US37213995A Continuation-In-Part 1995-01-13 1995-01-13

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US08/679,330 Continuation-In-Part US6348208B1 (en) 1995-01-13 1996-07-12 Methods and pharmaceutical compositions employing desmethylselegiline
US08/679,328 Continuation-In-Part US6033682A (en) 1995-01-13 1996-07-12 S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US09/940,252 Continuation-In-Part US6528082B2 (en) 1995-01-13 2001-08-27 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
US10/382,126 Continuation-In-Part US20030191191A1 (en) 1995-07-31 2003-03-04 Methods for preventing and treating peripheral neuropathy by administering desmethylselegiline delivery compositions

Publications (2)

Publication Number Publication Date
WO1996022068A2 WO1996022068A2 (fr) 1996-07-25
WO1996022068A3 true WO1996022068A3 (fr) 1996-11-14

Family

ID=23466867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/001561 WO1996022068A2 (fr) 1995-01-13 1996-01-11 Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline

Country Status (4)

Country Link
JP (1) JP3036847B2 (fr)
CN (1) CN100360123C (fr)
FI (1) FI972988A7 (fr)
WO (1) WO1996022068A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) * 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
EP0808160A1 (fr) * 1995-02-10 1997-11-26 The University Of Toronto Innovations Foundation Composes deprenyle pour le traitement du glaucome
DE19716905C1 (de) * 1997-04-22 1998-08-27 Iip Inst Fuer Ind Pharmazie Fo Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
EP1621190A1 (fr) * 1998-10-09 2006-02-01 L. Sai Latha Shankar Analogues du deprenyle pour traiter la sclérose en plaques
WO2000021513A2 (fr) * 1998-10-09 2000-04-20 Shankar L Sai Latha Procedes pour traiter la sclerose en plaques
AU8679801A (en) * 2000-08-28 2002-03-22 Somerset Pharmaceuticals Inc Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
WO2003059336A1 (fr) * 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methodes de traitement de troubles de la vue
MXPA04008574A (es) * 2002-03-04 2005-07-13 Somerset Pharmaceuticals Inc Metodos para prevenir y tratar neuropatia periferica al administrar desmetilselegilina.
CN116239476A (zh) * 2022-11-28 2023-06-09 安徽贝克制药股份有限公司 一种盐酸司来吉兰异构体的制备方法
CN116077419B (zh) * 2023-02-24 2023-10-27 丽珠集团新北江制药股份有限公司 一种犬用盐酸司来吉兰透皮吸收剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192550A (en) 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
CA2039194C (fr) 1990-08-31 1997-01-28 Norton W. Milgram Utilisations de l-deprenyl et de compositions qui en derivent
AU677842B2 (en) 1993-04-06 1997-05-08 Abbvie Inc. Tetracyclic compounds as dopamine agonists
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B.NICKEL ET AL.: "Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats", J.NEURAL.TRANSM., vol. 32, no. suppl, 1990, pages 139 - 144, XP000579887 *
C.H.WILLIAMS ET AL.: "BIOCHEMICAL AND BEHAVIOURAL STUDIES OF MONOAMINE OXIDASE INHIBITION", IR.J.MED.SCI., vol. 147, no. suppl.1, 1978, pages 71 - 74, XP000579843 *
E.H.HEINONEN ET AL.: "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects", NEUROLOGY, vol. 43, no. 4Suppl.2, April 1993 (1993-04-01), pages A156, XP000579857 *
E.H.HEINONEN ET AL.: "Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites", CLIN.PHARMACOL.THER., vol. 56, no. 6Pt2, December 1994 (1994-12-01), pages 742 - 749, XP000579881 *
E.H.HEINONEN ET AL.: "Pharmacokinetics and metabolism of selegiline", ACTA NEUROL.SCAND., vol. 126, 1989, pages 93 - 99, XP002014247 *
H.O.BORBE ET AL.: "Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat", J.NEURAL.TRANSM., vol. 32, no. suppl, 1990, pages 131 - 137, XP000579888 *
M.D.GERSHON ET AL.: "MONOAMINE OXIDASE INHIBITION AND THE INDUCTION OF PONTO-GENICULO-OCCIPITAL WAVE ACTIVITY BY RESERPINE IN THE CAT", J. PHARMACOL.EXP.THER., vol. 197, no. 3, 1976, pages 556 - 566, XP000579842 *
Y.C.MARTIN ET AL.: "Regression Analysis of the Relationship between Physical Properties and the in Vitro Inhibition of Monoamine Oxidase by Propynylamines", J.MED.CHEM., vol. 18, no. 9, 1975, pages 883 - 888, XP000579829 *

Also Published As

Publication number Publication date
JP3036847B2 (ja) 2000-04-24
WO1996022068A2 (fr) 1996-07-25
CN1178462A (zh) 1998-04-08
JPH10510542A (ja) 1998-10-13
FI972988A0 (fi) 1997-07-14
FI972988L (fi) 1997-09-11
FI972988A7 (fi) 1997-09-11
CN100360123C (zh) 2008-01-09

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
CA2230314A1 (fr) Formulations pharmaceutiques contenant de la darifenacine
WO1996022068A3 (fr) Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline
CA2093806A1 (fr) Methode de traitement ou de prevention du diabete de type 1 par l&#39;administration orale d&#39;insuline
AU7921887A (en) Therapeutic agents
FI935847A0 (fi) L-DOPA-esterkompositioner
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
US4425363A (en) Treatment of tardive dyskinesia in mammals
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
DK1212060T3 (da) Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom
CA2038744A1 (fr) Composition pharmaceutique contenant un medicament legerement hydrosoluble
CA2243237A1 (fr) Utilisation de valaciclovir dans la fabrication d&#39;un medicament destine au traitement de l&#39;herpes genital
JPH10512573A (ja) セスキテルペンラクトンとビタミンｂ複合体とを含む片頭痛およびその他の疾病治療用複合剤
EP1027053A4 (fr) Procede pour prevenir la nephrotoxicite resultant de l&#39;administration de cyclosporine et de tacrolimus
DE3873232T2 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
WO2000071109A3 (fr) S-(+)-desmethylselegiline et son utilisation therapeutique
CA2078869A1 (fr) Compositions pharmaceutiques contenant de l&#39;ipriflavone, leur procede de preparation et leur emploi therapeutique relatif
EP0294914A3 (fr) Nédocromil pour le traitement des maladies dermatologiques
EP0171227A1 (fr) Utilisation de propiophénone
CA2209892A1 (fr) Procedes et compositions pharmaceutiques utilisant de la desmethylselegiline
US4469700A (en) Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
US5229394A (en) Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
DE3664869D1 (en) Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein
EP0383481A3 (fr) Compositions anesthésiques buccales
US5472947A (en) Application of 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192486.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 08679330

Country of ref document: US

Ref document number: 08679328

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2209892

Country of ref document: CA

Ref document number: 2209892

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 972988

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1996904573

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996904573

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载